{"denoms":[{"counts":[{"groupId":"BG000","value":"1709"},{"groupId":"BG001","value":"1711"},{"groupId":"BG002","value":"3420"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to receive the matching placebo subcutaneously (SC) once every 6 months (Q6M) in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"BG000","title":"Placebo"},{"description":"Participants randomized to receive 60 mg denosumab SC once Q6M in the double-blind phase. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.","id":"BG001","title":"Denosumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.0","value":"64.6"},{"groupId":"BG001","spread":"7.9","value":"64.0"},{"groupId":"BG002","spread":"8.0","value":"64.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1709"},{"groupId":"BG001","value":"1711"},{"groupId":"BG002","value":"3420"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1700"},{"groupId":"BG001","value":"1702"},{"groupId":"BG002","value":"3402"}],"title":"White/Caucasian"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"}],"title":"Hispanic/Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Black/Afro-Caribbean"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"632"},{"groupId":"BG001","value":"633"},{"groupId":"BG002","value":"1265"}]}],"title":"Major Academic Center"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1077"},{"groupId":"BG001","value":"1078"},{"groupId":"BG002","value":"2155"}]}],"title":"Other Center"}],"paramType":"NUMBER","title":"Stratification Factor: Type of Hospital","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"270"},{"groupId":"BG002","value":"539"}],"title":"No"},{"measurements":[{"groupId":"BG000","value":"1440"},{"groupId":"BG001","value":"1441"},{"groupId":"BG002","value":"2881"}],"title":"Yes"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Prior Aromatase inhibitor Use","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"775"},{"groupId":"BG001","value":"773"},{"groupId":"BG002","value":"1548"}],"title":"T-score < -1.0"},{"measurements":[{"groupId":"BG000","value":"934"},{"groupId":"BG001","value":"938"},{"groupId":"BG002","value":"1872"}],"title":"T-score ≥ -1.0"}]}],"description":"T-scores are standardized scores that reflect the standard deviations (SDs) above/below the normal mean for young adults.\n\nT-score ≥ -1.0: BMD is considered normal.\n\nT-score \\< -1.0: Low BMD.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Total Lumbar Spine BMD T-score","unitOfMeasure":"Participants"}]}